We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Om39.0
Omega-3 Research
Probably helpsHigh safety
63 peer-reviewed studies
What the evidence says
Probably helps
Omega-3 helped in about half (15/23) of the studies that measured an effect — promising, but not unanimous.
Most evidence is from high-quality meta-analyses and randomised trials published 2015–2026 with a typical study size of 1,830 participants.
Based on 63 studies · 38 meta-analyses · 10 RCTs · 539,263 total participants
Confidence
High
What the studies found
15helped6unclear2didn't help· 40 more without graded effect data
By outcome
Heart & blood pressureImproved triglycerides and cardiovascular markers within 4-8 weeks · 4-8 weeks
Joint pain & arthritisReduced joint inflammation and stiffness within 4-8 weeks · 4-8 weeks
Too few graded studies1 study
Vision & eye health
Too few graded studies1 study
Fertility & reproductiveMay support reproductive health and fertility markers · 4-12 weeks
Too few graded studies1 study
By the numbers
Pulled from 60 studies with measurable effects
Likely real effects
90%
across studies
People studied
539k
typical study: 1830 people
Strongest designs
48
38 pooled, 10 randomised
Showed benefit
65%
15/23 studies
How long studies ran
1–3 months
1
3+ months
6
Populations Studied
General population4
Pregnant women3
Adults3
Cardiovascular patients3
Active research area
52 studies in the last 5 years · Latest meta-analysis: 2026
201520202026
1muscle strength, endurance, and recoveryMeta-Analysisn=1,211 · large study2026
These findings reveal an outcome-specific efficacy pattern supporting targeted supplementation strategies aligned with primary training objectives in athletic populations.
Wang Z et al. · Nutrients (2026)
The analysis incorporated 35 trials enrolling 1211 participants.
Network consistency assessment revealed no significant disagreement between direct and indirect evidence across all outcomes.
These findings reveal an outcome-specific efficacy pattern supporting targeted supplementation strategies aligned with primary training objectives in athletic populations.
2Depressive disorder symptomsMeta-AnalysisCited 1×n=17,437 · very large study2025
This extensive systematic review and NMA of nutraceuticals for treating depressive disorders indicated a number of nutraceuticals that could offer benefits, either as adjuncts or monotherapies.
Cheng YC et al. · Psychological medicine (2025)
Adjunctive nutraceuticals consistently showed better efficacy than antidepressants (ADT) alone in outcomes including SMD, remission, and response.
This extensive systematic review and NMA of nutraceuticals for treating depressive disorders indicated a number of nutraceuticals that could offer benefits, either as adjuncts or monotherapies.
3Type 2 diabetes incidenceMeta-AnalysisCited 9×n=5,205 · very large study2025
This meta-analysis examined the effects of Omega-3.
Tobias DK et al. · Nature communications (2025)
No clear effect
← WorseNo effectBetter →
Mean body mass index (BMI) was 27.5 kg/m2 (SD = 5.3), with 51% female and 17% Black race/ethnicity.
T2D incidence (cases/1000py) at median follow-up of 5.3 y was 3.98 for vitamin D and 4.37 for placebo (hazard ratio [HR] = 0.91; 95% confidence interval [CI] = 0.76, 1.09).
In conclusion, Vitamin D supplementation did not reduce T2D in older US adults, but a modest reduction was observed when meta-analyzed with prior trials.
4Ankle-brachial indexMeta-AnalysisCited 2×n=1,830 · large study2024
The evidence is very uncertain about the effect of omega-3 fatty acids in people with intermittent claudication on quality of life, walking distance (pain-free or maximal), ankle-brachial index, and the incidence of revascularisation procedures or frequency of amputation in the lower limb.
Mohammady M et al. · The Cochrane database of systematic reviews (2024)
No clear effect
← WorseNo effectBetter →
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
The evidence is very uncertain about the effect of omega-3 fatty acids in people with intermittent claudication on quality of life, walking distance (pain-free or maximal), ankle-brachial index, and the incidence of revascularisation procedures or frequency of amputation in the lower limb.
The evidence suggests that omega-3 results in little to no difference in adverse events.
5Cognitive decline progressionMeta-AnalysisCited 13×n=2,766 · very large study2024
The CDR scale showed reduced progression of cognitive decline among patients with n-3-PUFA supplemental interventions, with no differences between different n-3-PUFA supplements.
Calderon Martinez E et al. · Neuropsychopharmacology reports (2024)
Noticeable benefit
← WorseNo effectBetter →
Most publications described positive cognitive outcomes from supplements (58%).
CDR scale showed reduced progression of cognitive decline (SMD = -0.4127, 95% CI: [-0.5926; -0.2327]), without subgroup differences between different dietary supplement interventions.
However, Souvenaid® showed a significant negative effect (SMD = -0.3593, 95% CI: -0.5834 to -0.1352) in ventricular volumes.
6Migraine prophylaxisMeta-AnalysisCited 15×n=6,616 · very large study2024
Migraine is a highly prevalent neurologic disorder with prevalence rates ranging from 9% to 18% worldwide.
Tseng PT et al. · Advances in nutrition (Bethesda, Md.) (2024)
No clear effect
← WorseNo effectBetter →
Migraine is a highly prevalent neurologic disorder with prevalence rates ranging from 9% to 18% worldwide.
Current pharmacologic prophylactic strategies for migraine have limited efficacy and acceptability, with relatively low response rates of 40% to 50% and limited safety profiles.
Forty RCTs were included (N = 6616; mean age = 35.0 y; 78.9% women).
7Anxiety symptomsMeta-AnalysisCited 7×n=2,189 · very large study2024
The present dose-response meta-analysis suggested evidence of very low certainty that supplementation with omega-3 fatty acids may significantly improve anxiety symptoms, with the greatest improvements at 2 g/d.
Bafkar N et al. · BMC psychiatry (2024)
Large benefit
← WorseNo effectBetter →
Each 1 gram per day supplementation with omega-3 fatty acids resulted in a moderate decrease in anxiety symptoms (SMD: -0.70, 95%CI: -1.17, -0.22; GRADE = low).
The non-linear dose-response analysis indicated the greatest improvement at 2 g/d (SMD: -0.93, 95%CI: -1.85, -0.01), and that supplementation in a dose lower than 2 g/d did not affect anxiety symptoms.
Omega-3 fatty acids did not increase adverse events (odds ratio: 1.20, 95%CI: 0.89, 1.61; GRADE = moderate).
8Preeclampsia riskMeta-AnalysisCited 2×n=8,004 · very large study2024
Based on the results of the present study, the consumption of omega-3 supplementation and fish oil significantly reduces the risk of developing preeclampsia.
Rajati M et al. · Clinical nutrition ESPEN (2024)
Based on the results of the present study, the consumption of omega-3 supplementation and fish oil significantly reduces the risk of developing preeclampsia.
9Cardiovascular outcomesMeta-AnalysisCited 7×n=40,991 · very large study2024
Our research reinforces that all patients, regardless of their cardiovascular health, may benefit from adding omega-3 fatty acids to their statin therapy.
Irfan A et al. · Current problems in cardiology (2024)
In contrast, our analysis found no statistically significant difference in the incidence of fatal and non-fatal stroke, coronary revascularization, and cardiovascular mortality.
Our research reinforces that all patients, regardless of their cardiovascular health, may benefit from adding omega-3 fatty acids to their statin therapy.
10Anxiety and depressionMeta-AnalysisCited 40×n=1,426 · large study2023
Only one study reported significant reduction in anxiety severity with 2.1 g/day EPA (85.6% of total EPA + DHA), therefore meta-analysis was not possible.
Kelaiditis CF et al. · Prostaglandins, leukotrienes, and essential fatty acids (2023)
Only one study reported significant reduction in anxiety severity with 2.1 g/day EPA (85.6% of total EPA + DHA), therefore meta-analysis was not possible.
These results support the therapeutic potential of EPA in depression at proportions ≥ 60% of total EPA + DHA and doses ≥ 1 g/day and < 2 g/day.
11Incident atrial fibrillationMeta-AnalysisCited 37×n=54,799 · very large study2023
In vivo levels of omega-3 fatty acids including EPA, DPA, DHA, and EPA+DHA were not associated with increased risk of incident AF.
Qian F et al. · Journal of the American College of Cardiology (2023)
No clear effect
← WorseNo effectBetter →
In multivariable analysis, EPA levels were not associated with incident AF, HR per interquintile range (ie, the difference between the 90th and 10th percentiles) was 1.00 (95% CI: 0.95-1.05).
HRs for higher levels of DPA, DHA, and EPA+DHA, were 0.89 (95% CI: 0.83-0.95), 0.90 (95% CI: 0.85-0.96), and 0.93 (95% CI: 0.87-0.99), respectively.
In vivo levels of omega-3 fatty acids including EPA, DPA, DHA, and EPA+DHA were not associated with increased risk of incident AF.
15Multiple sclerosis relapsing rate and inflammatory markersSystematic ReviewCited 85×n=5,554 · very large study2021
These roles were attributed to their beneficial effects on inflammatory markers, glutathione reductase, reducing the relapsing rate, and achieving balanced omega-6 to omega-3 ratios.Conclusion: Omega-3 and fish oils supplementations have beneficial effects on reducing the relapsing rate, inflammatory markers, and improving the quality of life for MS patients.
AlAmmar WA et al. · Nutritional neuroscience (2021)
The inclusions were studies performed on humans both male and female, aged 18 years at minimum, diagnosed with MS according to McDonald 2010 criteria.
Otherwise, all studies were excluded.Results: A total of 5554 studies were screened and seven were thoroughly focused on as they typically met the inclusion criteria.
These studies showed the beneficial roles of fish oil supplementation and omega-3 fatty acids in improving the quality of life of MS patients.
17Patient important outcomes after myocardial infarctionMeta-AnalysisCited 15×n=24,414 · very large study2019
For adult patients with AMI, omega 3 fatty-acids probably yield no benefit to patient important outcomes.
Popoff F et al. · BMC cardiovascular disorders (2019)
No clear effect
← WorseNo effectBetter →
Regarding adverse events, we are uncertain if Omega 3 fatty acids improve/reduce non severe adverse events (RR 1.39 95% CI 0.36 to 5.34; very low certainty).
There is probably little or no difference in the outcome suspension due to adverse events (RR 1.19 CI 95% 0.97 to 1.47; moderate certainty).
For adult patients with AMI, omega 3 fatty-acids probably yield no benefit to patient important outcomes.
18Depressed moodMeta-AnalysisCited 48×n=4,605 · very large study2018
In the well-being mental health group, the Hedges g was 0.12 (95% confidence interval, -0.05 to 0.29), which indicated no significant effect of n-3 PUFA supplementation on depressed mood compared w...
Bae JH et al. · Nutrition research (New York, N.Y.) (2018)
Huge benefit
← WorseNo effectBetter →
In the well-being mental health group, the Hedges g was 0.12 (95% confidence interval, -0.05 to 0.29), which indicated no significant effect of n-3 PUFA supplementation on depressed mood compared with placebo.
In the depressive group, the pooled Hedges g was -0.94 (95% CI, -1.37 to -0.50]) for the random-effects model, which indicated a large effect of n-3 PUFA supplementation on those with depressed mood compared with placebo.
Although this review shows that omega-3 fatty acids are effective in the treatment of elderly depressed patients, the benefits of omega-3 fatty acid supplementation were significant only in the elderly patients with mild to moderate depression.
19Cardiovascular events and coronary revascularizationMeta-AnalysisCited 24×n=144 · medium study2024
Omega-3 fatty acid supplementation reduced the risk of cardiovascular events and coronary revascularization, regardless of background statin use.
Dinu M et al. · European journal of preventive cardiology (2024)
Noticeable benefit
← WorseNo effectBetter →
Likely real
Lower risk was still observed in trials where most participants (≥60%) were on statin therapy.
Compared with DHA + EPA, EPA alone showed a further significant risk reduction of revascularizations (0.76, 95% CI 0.65-0.88; P = 0.0002; P-interaction = 0.005) and all outcomes except HF.
Omega-3 fatty acid supplementation reduced the risk of cardiovascular events and coronary revascularization, regardless of background statin use.
The find-ings highlight the heterogeneity in responses to omega-3 fatty acid supplementation and emphasize the need for cautious interpretation.
Fei L et al. · Asia Pacific journal of clinical nutrition (2024)
The meta-analysis revealed a neutral overall effect size of omega-3 fatty acid supplementation on proteinuria levels, assessed under both common and random effect models.
Despite the lack of statistically significant evidence supporting the efficacy of omega-3 fatty acids in reducing proteinuria, the variability in interventions and patient populations suggests potential individual responses.
The find-ings highlight the heterogeneity in responses to omega-3 fatty acid supplementation and emphasize the need for cautious interpretation.